Vertex Net Interest Income from 2010 to 2026
| VRTX Stock | USD 470.31 7.01 1.47% |
Net Interest Income | First Reported 2019-03-31 | Previous Quarter 122.4 M | Current Value 118.6 M | Quarterly Volatility 71.2 M |
Check Vertex Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Vertex Pharmaceuticals' main balance sheet or income statement drivers, such as Total Revenue of 12.7 B, Gross Profit of 10.8 B or Other Operating Expenses of 7.7 B, as well as many indicators such as Price To Sales Ratio of 9.12, Dividend Yield of 0.0 or PTB Ratio of 7.54. Vertex financial statements analysis is a perfect complement when working with Vertex Pharmaceuticals Valuation or Volatility modules.
Vertex | Net Interest Income | Build AI portfolio with Vertex Stock |
The evolution of Net Interest Income for Vertex Pharmaceuticals provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Vertex Pharmaceuticals compares to historical norms and industry peers.
Latest Vertex Pharmaceuticals' Net Interest Income Growth Pattern
Below is the plot of the Net Interest Income of Vertex Pharmaceuticals over the last few years. It is the difference between the revenue generated from a bank's interest-bearing assets and the expenses associated with paying its interest-bearing liabilities. Vertex Pharmaceuticals' Net Interest Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Vertex Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Net Interest Income | 10 Years Trend |
|
Net Interest Income |
| Timeline |
Vertex Net Interest Income Regression Statistics
| Arithmetic Mean | 85,761,824 | |
| Coefficient Of Variation | 300.92 | |
| Mean Deviation | 209,196,574 | |
| Median | (56,600,000) | |
| Standard Deviation | 258,077,797 | |
| Sample Variance | 66604.1T | |
| Range | 652M | |
| R-Value | 0.80 | |
| Mean Square Error | 25782.2T | |
| R-Squared | 0.64 | |
| Significance | 0.0001 | |
| Slope | 40,792,799 | |
| Total Sum of Squares | 1065666.4T |
Vertex Net Interest Income History
About Vertex Pharmaceuticals Financial Statements
Vertex Pharmaceuticals investors use historical fundamental indicators, such as Vertex Pharmaceuticals' Net Interest Income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Vertex Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Interest Income | 477.6 M | 501.5 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Vertex Stock Analysis
When running Vertex Pharmaceuticals' price analysis, check to measure Vertex Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vertex Pharmaceuticals is operating at the current time. Most of Vertex Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Vertex Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vertex Pharmaceuticals' price. Additionally, you may evaluate how the addition of Vertex Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.